The multi-modal approach leverages additional information from the patient's tumor sample, using Natera's AI models trained on long-term molecular and clinical outcomes from Natera's proprietary ...
AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The result is one molecule that can be both a checkpoint degrader and a cancer vaccine ( Nature 2026, DOI: 10.1038/s41586-025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback